Date de publication: 12 mai 2009
Promoteur – Intermédiaire Financier
A family-owned, mid-sized pharmaceutical company.Lieu
Description
The project concerns the investment in research and development of new pharmaceutical compounds in the area of CNS (Central Nervous System), Respiratory Diseases and Metabolic Diseases (in particular diabetes).
Objectifs
New pharmaceutical products in the area of CNS, Metabolism and Respiratory.
Secteur(s)
Montant BEI envisagé (montant approximatif)
EUR 400 million.
Aspects environnementaux
R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An EIA therefore is not required by EU Directive 97/11. Compliance of R&D activities with relevant EU legislation in particular in regards to animal testing will also be verified during appraisal.
Passation des marchés
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. Procedures followed will be verified during appraisal.
Statut
Signé - 28/10/2009